Search

"Efficacy and safety of bleselumab in kidney transplant recipients: A phase 2, randomized, open-label, noninferiority study"

Originally aired on Tuesday, December 3rd, 2019 • Hosted by the Transplant Pharmacy Community of Practice (TxPharm COP)

"Efficacy and safety of bleselumab in kidney transplant recipients: A phase 2, randomized, open-label, noninferiority study."
(Am J Transplant. 2019 Sep 11. doi: 10.1111/ajt.15591. [Epub ahead of print])

In this article:
This study assessed the efficacy and safety of the anti-CD40 monoclonal antibody bleselumab (ASKP1240) in de novo kidney transplant recipients over 36 months posttransplant.... For the primary endpoint (incidence of biopsy-proven acute rejection [BPAR] at 6 months), bleselumab + IR-TAC was noninferior to SoC, and bleselumab + MMF did not demonstrate noninferiority to SoC. BPAR incidence slightly increased through month 36 in all groups, with bleselumab + IR-TAC continuing to demonstrate noninferiority to SoC. Bleselumab had a favorable benefit-risk ratio. Most treatment-emergent adverse events were as expected for kidney transplant recipients (see also ClinicalTrials.gov NCT01780844).

Speaker:
Bharath Ravichandran, PharmD • University of Maryland Medical Center, Baltimore, MD

Moderator:
Stephen Jensik, MD • Rush University Medical Center, Chicago, IL

Watch Video

AST/AJT Journal Club

See all Journal Clubs

Donate

Donate

Donate

to the American Society of Transplantation

Career Center

Career Center

Career Center

Connecting Transplantation Talent with Opportunities

Patient Education

Patient Education

Educating the Community

The AST initiative, Power2Save, has great resources for patients and patient families.

Educational Content Disclaimer: The content, information, opinions, and viewpoints contained in educational materials housed on and linked from the AST web site are those of the authors or contributors of such materials. While the AST and its committees take great care to screen the credentials of the contributors and make every attempt to review the contents, AST MAKES NO WARRANTY, EXPRESSED OR IMPLIED, as to the completeness or accuracy of the content contained in the educational materials or on this website. The reader of these materials uses these materials at his or her own risk, and AST shall not be responsible for any errors, omissions, or inaccuracies in these materials, whether arising through negligence, oversight, or otherwise. Reliance on any information appearing on this site is strictly at your own risk. Read the full disclaimer.